Current CEO Timo Lehtonen is transferring into a new role in the company, according to te release. During his tenure he saw the company through the first FDA market authorization of magnesium-based implants.
Mr. Lehtonen will stay with the company until a successor is appointed.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
